Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

Novo Nordisk · Phase 2 · Completed · Enrollment 834

NCT03235050

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

3186592
≥5%
≥10%
≥15%
≥20%
  • Placebo + Metformin
  • MEDI0382 100 mcg
  • MEDI0382 200 mcg
  • MEDI0382 300 mcg
Show as table
Arm≥5%≥10%≥15%≥20%
MEDI0382 low dose + Metforminn/rn/rn/rn/r
MEDI0382 mid dose + Metforminn/rn/rn/rn/r
MEDI0382 high dose + Metforminn/rn/rn/rn/r
Placebo + Metformin3%n/rn/rn/r
Liraglutide + Metforminn/rn/rn/rn/r
MEDI0382 100 mcg18%n/rn/rn/r
MEDI0382 200 mcg65%n/rn/rn/r
MEDI0382 300 mcg92%n/rn/rn/r

Not shown

  • MEDI0382 low dose + Metformin: endpoint not reported
  • MEDI0382 mid dose + Metformin: endpoint not reported
  • MEDI0382 high dose + Metformin: endpoint not reported
  • Liraglutide + Metformin: endpoint not reported